Evidence map›Paper›PMID 33767957›Full record

ArticleTaiwan journal of ophthalmology

Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial.

Karen R Armbrust, Austin R Fox, Brett G Jeffrey, Patti Sherry, H Nida Sen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Serum antiretinal antibodies and cytokine profiling in autoimmune retinopathy and their association with clinical outcomes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Article
  4. Management of autoimmune retinopathy treated with intravitreal dexamethasone implant.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Article
  5. Rituximab for non-infectious Uveitis and Scleritis.Journal of ophthalmic inflammation and infection · 2021
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Karen R ArmbrustLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Austin R FoxLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Brett G JeffreyLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Patti SherryLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
H Nida SenLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
National Eye Institute · USNational Institutes of Health · USUniversity of Iowa · USUniversity of Minnesota Medical Center · US

Funding

Studies of Ocular inflammation: Translational ResearchZIAEY000556 · NEI · NATIONAL EYE INSTITUTE · PI CASPI, RACHEL R. · 2017 to 2025
$11.3M
6 · The paper itself

Abstract

purposeThis prospective study evaluates whether rituximab is a safe and potentially effective treatment for nonparaneoplastic autoimmune retinopathy (npAIR). MATERIALS AND

methodsFive npAIR patients were enrolled in a Phase I/II, prospective, nonrandomized, open-label, single-center study. All patients received a cycle of 1000 mg intravenous rituximab at weeks 0 and 2, with a second cycle of rituximab 6 to 9 months later. Clinical evaluation was performed at baseline, 6 and 12 weeks after each rituximab cycle, and then every 3 months for a total duration of 18 months. The primary outcome for this study was treatment success based on visual field and full-field electroretinography at 6 months. The secondary outcomes included treatment success at months 12 and 18, drug-related adverse events, changes in visual symptoms, and changes in quality of life.

resultsTwo patients met criteria for treatment success: one based solely on electroretinography and the other based solely on visual field area, but treatment success was not sustained. Clinical response over the course of the 18-month study showed disease stabilization in three patients and treatment failure in two patients. There were no severe drug-related adverse events.

conclusionThis is the first clinical trial prospectively evaluating the effect of rituximab in npAIR and, although rituximab was well tolerated, there was no clear-cut clinical improvement conferred by B cell depletion with rituximab.

Indexed as

Autoimmunityelectroretinographyretinal degenerationrituximabvisual fields

Identifiers

PMID33767957
PMCPMC7971443
OpenAlexW3045551362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.